Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Cardiff, South Wales, United Kingdom Clinical Trials

A listing of Cardiff, South Wales, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (8) clinical trials

Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)

PATHOS is a multicentre, open label, parallel group Phase II/III randomised controlled trial (RCT). Approximately 242 patients will be recruited to the phase II study. Patients eligible for the study must have biopsy proven oropharyngeal squamous cell carcinoma (OPSCC) clinically staged T1T3 N0N2b. Their primary tumour, as judged by the ...

Phase

1.8 miles

Learn More »

Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations

AML18 is a trial primarily for older patients with AML and high risk Myelodysplastic Syndrome (MDS). It offers a randomised controlled Phase II/III trial which uses a factorial design for maximum efficiency to evaluate two induction options followed by treatment with small molecule beyond course 1, and dose intensification for ...

Phase

1.81 miles

Learn More »

Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme versus placebo in patients with malignant pleural mesothelioma with low argininosuccinate synthetase 1 expression. Malignant pleural mesothelioma have been found to require arginine, an amino acid. Thus the hypothesis is that by restricting arginine with ADI-PEG ...

Phase

3.22 miles

Learn More »

Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer

OBJECTIVES Primary Assess the safety and efficacy of neoadjuvant and adjuvant chemotherapy comprising epirubicin hydrochloride, cisplatin, and capecitabine with or without bevacizumab in patients with previously untreated, resectable gastric, gastroesophageal junction or lower oesophageal cancer. Assess the safety of neoadjuvant and adjuvant chemotherapy comprising epirubicin hydrochloride, cisplatin, and capecitabine with ...

Phase

3.22 miles

Learn More »

Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy

STAMPEDE (also known as MRC PR08) is a multi-arm multi-stage (MAMS) randomised controlled trial recruiting in the UK and Switzerland. It aims to evaluate multiple therapeutic strategies in the management of high-risk locally advanced and metastatic hormone-nave prostate cancer. Each novel treatment strategy is compared against a single, contemporaneous control ...

Phase

3.22 miles

Learn More »

Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation

Research has shown that increasing the dose of radiotherapy improves outcomes in patients with lung and head and neck cancers. This study aims to see whether this is also the case for patients with tumour of the oesophagus. This trial will compare the effects of the standard dose of radiotherapy ...

Phase

3.22 miles

Learn More »

A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered Locally Advanced or Metastatic Triple-Negative Breast Cancer or Hormone Receptor-Positive HER2-Negative Breast Cancer

This study will evaluate the efficacy of ipatasertib + paclitaxel versus placebo + paclitaxel in participants with histologically confirmed, locally advanced or metastatic triple-negative breast cancer (TNBC) and in participants with locally advanced or metastatic hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2) breast adenocarcinoma who ...

Phase

3.22 miles

Learn More »

IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients

Phase II: to determine if recruitment into a phase III trial is feasible, with a target of 10 patients per month during a minimum of 6 months (evaluated within months 7-18 of the trial). Phase III: to determine whether the 5-year disease-free survival rate among patients who do not have ...

Phase

7.21 miles

Learn More »